Symetrica Appoints David Price As Chairman

June 23rd, 2015|

Symetrica, the Technology Venture Partners portfolio company providing radiation detection solutions company has announced the appointment of David Price as Non-executive Chairman.

David Price was formerly CEO of Chemring Group plc, the FTSE 250 listed with revenues of £600m. Chemring is a specialist manufacturer of expendable countermeasures, advanced electronics and energetic materials for the global defence, security and safety markets. Prior to Chemring, David was MD of Rolls Royce Naval Marine, a division supplying propulsion systems, products & services to 59 navies for both submarine and surface ship applications. Naval Marine is a global business with a turnover of over £450m per year and employing 2900 staff. It undertook the design authority role for all Royal Navy nuclear reactor systems and manufactured all of the key components for the Pressurised Water Reactor.

[Read More]

Micrima’s radiowave breast cancer detection system gains EU regulatory approval

April 29th, 2015|

Micrima, the Bristol company developing a safe, low-cost way of improving breast cancer detection, has gained CE marking for its MARIA (Multistatic Array processing for Radiowave Image Acquisition) product, paving the way for further supportive clinical trials in the UK and expansion into Europe.

[Read More]

Atlas completes $20 million Series C fundraising

January 29th, 2015|

Funds to accelerate global launch of Atlas io® molecular testing system

Bath, UK, 29 January, 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), the ultra-rapid ‘test and treat’ molecular diagnostics company, today announces the completion of a Series C financing, raising $20 million from a syndicate including existing investors and one new investor, RMI Partners. New investor, RMI Partners, is a global life sciences venture capital firm, the largest in Eastern Europe. Existing investors include Novartis Venture Funds, Consort Medical plc, Johnson & Johnson Innovation – JJDC, Inc., LSP, BB Biotech Ventures and Technology Venture Partners. This newly announced financing follows on from the previously announced Series B fundraising of $25 million.

[Read More]

Bristol venture team set up Technology Venture Partners in spin-out from YFM Equity Partners

May 23rd, 2014|

The Bristol team of YFM Equity Partners have taken over managing the South West Ventures Fund through a newly formed independent venture capital fund manager, Technology Venture Partners.

The South West Ventures Fund was established as one of the UK’s nine Regional Venture Capital Funds to invest up to £2m of risk capital into high growth small businesses. The fund is now fully invested and the portfolio includes Dynmark, a cloud based mobile intelligence and messaging platform and Micrima, which has developed innovative technology for breast cancer screening based on radiowaves instead of X-rays.

The spin-out will see the South West Ventures Fund continue to be managed by the three founding partners of Technology Venture Partners, Peter Davies, Nick Simmonds and Julian Dennard. Technology Venture Partners will focus on investing in emerging UK technology companies.

[Read More]